source
- Scribe records upsized $129M IPO to bankroll lipid-lowering genetic medsIn vivo gene editing outfit Scribe Therapeutics has priced its IPO at $128.7 million, surpassing the $96 million goal set out earlier this week.Fierce Biotech · 8d ago↗ source
- Chutes & Ladders—Biogen R&D vet gets in FormationAI-focused Formation Bio has found a new chief scientist with extensive experience in biotech, Big Pharma and academia. Michael Ehlers, M.D., Ph.D., is joining the 2025 Fierce 15 honoree as chief s…Fierce Biotech · 9d ago↗ source
- From Abu Dhabi to Brazil, every region is vying for the ‘new emerging economy’ of biotechWhether it's looming tariff threats or the rise of China, you need a truly global view to navigate today's biopharma industry.Fierce Biotech